New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
January 9, 2014
07:17 EDTMDTMedtronic's SYMPLICITY HTN-3 trial fails to meet primary efficacy endpoint
Medtronic announced that its U.S. pivotal trial in renal denervation for treatment-resistant hypertension, SYMPLICITY HTN-3, failed to meet its primary efficacy endpoint. The trial met its primary safety endpoint, and the trial's Data Safety Monitoring Board concluded that there were no safety concerns in the study. Based on these clinical trial findings, Medtronic intends to formulate a panel of independent advisors made up of physicians and researchers who will be asked to make recommendations about the future of the global hypertension clinical trial program, as well as provide advice on continued physician and patient access to the Symplicity technology in countries with regulatory approvals.
News For MDT From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
November 27, 2015
06:59 EDTMDTMedtronic volatility flat into Q2 and outlook
Subscribe for More Information
November 24, 2015
08:31 EDTMDTMedtronic remains a top tier performer in Med Device space, says Cowen
Subscribe for More Information
November 20, 2015
05:22 EDTMDTStocks with implied volatility movement; MDT UNH
Stocks with implied volatility movement; Medtronic (MDT) 25, UnitedHealth (UNH) 30 according to iVolatility.
November 17, 2015
09:14 EDTMDTMedtronic announces FDA approval, launch of MyCareLink Smart Monitor
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.
I agree to the disclaimer & terms of use